UNSPSC 51332880: Trifluoperazine hydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P1Y2SNF5V, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)- but more generally known as trifluoperazine hydrochloride, which bears US NIH Compound Identifier 5566. European Medicines Agency schedules Trifluoperazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04956MIG.

UNSPSC 51332880 Trifluoperazine hydrochloride is a Commodity code that nominally names a single pharmaceutical active ingredient, but recent state and local procurement activity under this code does not involve trifluoperazine specifically. Instead, the opportunities tagged to this code reflect broader pharmaceutical and pharmaceutical-adjacent procurement — naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program capabilities. State and local governments are using this code to solicit pharmaceuticals for community health initiatives, generic drug supply agreements, and pharmacy benefit program infrastructure. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The mismatch between the code's nominal scope and actual procurement activity suggests either a cataloging error or a broad catch-all application of the code to pharmaceutical procurement that extends well beyond trifluoperazine.

Activity appears concentrated in Florida and Minnesota, with additional engagement from Texas at the state level. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs without issuing a formal solicitation. The lack of alignment between the code's stated pharmaceutical ingredient and the actual procurements limits this code's utility for targeting specific pharmaceutical supply opportunities.